mezombie
Senior Member
- Messages
- 324
- Location
- East Coast city, USA
Study authors respond
This was posted this evening on Co-Cure by Stephen Ralph. I'm too brain-dead to discuss it and am certainly not posting it to defend the authors; I'm adding it simply for informational purposes. I'll leave it to others to dissect.
--Marie
----------------------------------
http://www.plosone.org/annotation/listThread.action?inReplyTo=info:doi/1
0.1371%2Fannotation%2F13ea20d1-91e6-49c3-bc4b-8fd1ca18f150&root=info%3Adoi%2
F10.1371%2Fannotation%2F13ea20d1-91e6-49c3-bc4b-8fd1ca18f150
Authors Response
Original Article Failure to Detect the Novel Retrovirus XMRV in Chronic
Fatigue Syndrome
Authors Response
Posted by Anthony_Cleare on 12 Jan 2010 at 19:55 GMT
As the clinicians and scientists who provided the samples that were tested
at Imperial, we wish to respond to some of the comments here and elsewhere
regarding the patients who provided these samples.
In the paper we provided extensive details of the sample selection,
criteria, assessments and investigations that are routine in our service,
together with references/citations to all the material
To re iterate.
1. The criteria that we use are the Fukuda et al 1994 criteria that are far
and away the most widely used across the world and in the research
literature. We do not use the so-called "Canadian criteria", which are
designed for clinical use, not operationalised and do not translate easily
for use in research. Even so, had we attempted to do so, a substantial
proportion would have also met these clinical criteria.
2. The patients resembled those seen in secondary care and tertiary care
services elsewhere - most particularly they are similar to those seen in
clinics in Australia, USA, Scotland, England and Northern Ireland (Wilson et
al, 2001; Hickie et al, 2009).
3. We follow the same psychiatric exclusion criteria as mandated by the
Fukuda criteria. We do this on the basis of semi structured interviews and
assessment that we have also published. In addition, we also exclude
patients with chronic somatisation disorder as defined by DSM-IV, which is
not required by the Fukuda criteria, but most experts and clinicians agree
are a different population. This is only a small percentage of our
referrals.
4. In answer to one question, yes, our patients all report both mental and
physical fatigue, exacerbated by mental or physical effort. Nearly all also
describe post exertional fatigue and malaise.
5. We have a standard laboratory protocol for investigations, which are
performed on all those referred to the clinic, unless they have been done
recently by the referring doctor. These are solely for the purpose of
excluding other diseases that can sometimes mimic CFS, and are part of the
differential diagnosis. This is standard practice in every CFS service of
which we are aware and forms part of every definition of which we are aware,
including the "Canadian criteria". In addition to the standard work up, we
also now routinely test for coeliac disease, because we found a 2%
prevalence of undetected coeliac disease (Skowera et al, 2001). In answer to
another question, we perform a 9.00 am cortisol as a screener for Addison's
disease.
6. In addition we also perform tests as part of research protocols. We
always tell patients that these additional tests and investigations are not
necessary clinically, and are performed with informed consent. Thus patients
in our service have also co operated in studies of PET and fMRI
neuroimaging, autonomic dysfunction, neurochemistry, respiratory function,
vitamin status, anti nuclear antibodies, immune function, neuroendocrine
function and genetics (see references). Hence it is untrue to state that
patients at King's for example do not show alterations in immune function -
in fact they do - see Skowera et al, High levels of type 2
cytokine-producing cells in chronic fatigue syndrome." Clinical and
Experimental Immunology 2004: 135: 294-302. Similarly, many of our patients
also show altered neuroendocrine, neurochemical and other biological
parameters, and we have published many examples of these (see references
below). It is therefore simply untrue that we either seek to find no
biological changes in CFS, or fail to report those that we do find.
7. On the other hand, it is true that those who receive a diagnosis of
cancer would be and are excluded from a diagnosis of CFS and if this is
detected they would be immediately referred to the relevant clinical
services. It is possible that this may be a difference from the cohort
originally reported in Science, if the Wall St Journal is correct
(http://online.wsj.com/art...).
8. We do not perform these additional tests to confirm or refute a diagnosis
of CFS, but to further understanding of the illness. If and when a properly
validated diagnostic test is developed for use within the National Health
Service, all our patients will be offered it free of charge, just as they
are already offered diagnostic assessment, investigation and treatment free
of charge.
9. We did not perform any selection in any shape or form of the samples that
we hold to send to Imperial College, as again has been suggested.
Overall, we wish to emphasis, and to do so emphatically, that our patients
are typical of CFS patients seen in specialist care elsewhere. We
specifically refute the suggestion that our patients are in some way more
"psychiatric", whatever that means, than those with "real CFS", an assertion
that has been repeatedly made in other venues. The rates of co morbid
psychiatric disorder, for which we routinely screen, are again similar to
those seen elsewhere. We draw attention to another study that compared two
services run in the same London teaching hospital, one by an immunologist,
the other a psychiatrist, but showed no fundamental differences between the
two (White et al, 2004). On behalf of the patients that attend our CFS
clinic, we resent the implication that they are in some way different, less
ill, less disabled, let alone less deserving, than CFS patients in any other
service or setting. It is otherwise, and we have provided a wealth of
published data to back this assertion.
Professor Simon Wessely, Professor of Psychological Medicine
Professor David Collier, Professor of Psychiatric Genetics
Dr Anthony Cleare, Reader in Neuroendocrinology
REFERENCES
Allain T, Bearn J, Coskeran P, Jones J, Checkley A, Butler J, McGregor A,
Wessely S, Miell J. Changes in growth hormone, insulin, insulin-like growth
factors (IGFs) and IGF-binding protein-1 in chronic fatigue syndrome. Biol
Psychiatry 1997;41:567-573
Bearn J, Allain T, Coskaran P, Miell J, Butler J, McGregor A, Wessely S.
Neuroendocrine responses to D-fenfluramine and insulin induced hypoglycaemia
in chronic fatigue syndrome. Biological Psychiatry 1995;37:245-252.
Caseras, X., David Mataix-Cols, Vincent Giampietro, Katharine A Rimes,
Michael Brammer, Fernando Zelaya, Trudie Chalder, Emma L Godfrey (2006).
"Probing the working memory system in Chronic Fatigue Syndrome: An fMRI
study using the n-back task." Psychosomatic Medicine 68: 947-955.
Caseras X, M.-C. D., Giampietro V, Rimes KA, Brammer M, Zelaya F, Chalder T,
Godfrey EL (2008). "The neural correlates of fatigue: A fatigue provocation
study in Chronic Fatigue Syndrome." Psychological Medicine 38: 1-11.
Cleare A, Bearn J, Allain T, Wessely S, McGregor A, O'Keane V. Contrasting
neuroendocrine responses in depression and chronic fatigue syndrome. J
Affective Disorder 1995;35:283-289.
Cleare AJ, Sookdeo S, Jones, J, O'Keane V, Miell J. Integrity of the GH/IGF
axis is maintained in chronic fatigue syndrome. Journal of Clinical
Endocrinology and Metabolism, 2000: 85: 1433-1439.
Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V.
Hypothalamo-Pituitary-Adrenal axis function in chronic fatigue syndrome, and
the effects of low-dose hydrocortisone therapy. Journal of Clinical
Endocrinology and Metabolism 2001: 86: 3545-3554.
Cleare AJ Keane, V, Miell JP et al. Levels of DHEA and DHEAS and responses
to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Psychoneuroendocrinology 2004;29:724-32.
Cleare AJ, Messa C, Rabiner E, Grasby P. Brain 5-HT1A receptor binding in
chronic fatigue syndrome measured using positron emission tomography and
[11C]WAY-100635. Biological Psychiatry 2005: 57, 239-246.
Di Giorgio A Hudson, Jerjes W, Cleare AJ. 24-hour pituitary and adrenal
hormone profiles in chronic fatigue syndrome. Psychosomatic Medicine.
2005;67:433-40.
Heap, L., Peters T, Wessely S. Vitamin B status in patients with chronic
fatigue syndrome Journal of the Royal Society of Medicine 1999: 92: 183-185.
Fritz E, Smith J, Kerr J, Cleare A, Wessely S, Mattey D. Association of
chronic fatigue syndrome with human leucocyte antigen class II alleles.
Journal of Clinical Pathology 2005;58:860-863.
Hickie I, Davenport T, Vernon S, Nisenbaum R, Reeves W, Hadzi Pavlovic D,
Lloyd A, Are chronic fatigue and chronic fatigue syndrome valid clinical
entities across countries and health care settings? Australian and NZ
Journal of Psychiatry, 2009; 43:25-35.
Jerjes WK, Cleare AJ, Wessely S, Wood P, Taylor NF. Diurnal patterns of
salivary cortisol and cortisone output in chronic fatigue syndrome J
Affective Disorder 2005: 87: 299-304.
Jerjes WT, NF; Wood, PJ; Cleare, AJ. Enhanced feedback sensitivity to
prednisolone in chronic fatigue syndrome. Psychoneuroendcrinology.
2007;32:192-8.
Jerjes W, Peters T, Taylor N, Wessely S, Cleare A. Diurnal excretion of
urinary cortisol, cortisone and cortisol metabolites in chronic fatigue
syndrome. J Psychosom Res 2006: 60: 145-153
Peakman M, Deale A, Field R, Mahalingam M, Wessely S. Clinical improvement
in chronic fatigue syndrome is not associated with lymphocyte subsets of
function or activation. Clin Immun Immunopath 1997;82:83-91.
Saisch S, Deale A, Gardner W, Wessely S. Hyperventilation and chronic
fatigue syndrome. Quarterly J Medicine 1994: 87:63-67.
Skowera, A., M. Peakman, et al. (2001). "High prevalence of serum markers of
coeliac disease in patients with chronic fatigue syndrome." Journal of
Clinical Pathology 54: 335-336.
Skowera A, Stewart E., Davis E, Cleare A, Hossain G, Unwin C, Hull L, Ismail
K, Wessely S, Peakman M (2002). "Antinuclear antibodies (ANA) in gulf war
related illness and chronic fatigue syndrome (CFS) patients." Clinical
Experimental Immunology 129: 354-358.
Skowera, A., Cleare, A., Blair, D., Bevis, L., Wessely, S., Peakman, M
(2004). "High levels of type 2 cytokine-producing cells in chronic fatigue
syndrome." Clinical and Experimental Immunology 135: 294-302.
Underhill, J., Donaldson P, Mahalingam, M., Wessely A, Peakman M. (2001).
"Lack of association between HLA and chronic fatigue syndrome." European
Journal of Immunogenetics 28: 425-428.
Wilson A, Hickie I, Hadzi-Pavlovic D, Wakefield D. Straus S, Dale J,
McCluskey D, Hinds, G, Brickman A, Goldenberg D, Demitrack M, Wessely S,
Sharpe M, Lloyd A. What is chronic fatigue syndrome? Heterogeneity within an
international, multicenter study. Australian & New Zealand J Psychiatry
2001: 35:520-527
White PD, Pinching AJ, Rakib A, Castle M, Hedge B, Priebe S. A comparison of
patients with chronic fatigue syndrome attending separate fatigue clinics
based in immunology and psychiatry. Journal of the Royal Society of Medicine
2002;95:440-4.
Winkler, A., Blair D, Marsden J, Peters T, Wessely S, Cleare A, (2004).
Autonomic function and serum erythropoetin levels in chronic fatigue
syndrome. Journal of Psychosomatic Research 56: 179-183.
Competing interests declared: Authors of the paper
=========================================
www.ialibrary.berr.gov.uk/.../45. EuP Domestic Lighting_v2 5.doc
Impact Assessment of EuP Implementing Measures of Domestic Lighting
Date: 1st December 2008
[ ... ]
Another clinician Dr Maurice Murphy 62 did not know of any evidence that
demonstrates that CFLs or any other lighting has any effect, detrimental or
otherwise, on CFS/ME. Some patients do indicate light sensitivity, but this
could be part of a general hypersensitivity to various stimuli. Dr Murphy
thought there may be a maladaptive response, for example patients confining
themselves indoors then finding it difficult to adapt to brighter lighting.
Proper evidence would require a controlled study but this would be difficult
practically.
Professor White 63 indicated that he would be surprised if radiation from
low energy lighting had a detrimental effect on patients with CFS/ME, but
would not be surprised if open studies supported such a relationship. This
is because, for some patients, the knowledge that they were being exposed to
radiation reported anecdotally to cause harm would be enough to cause such a
reaction. Dr White was not aware of any studies to test a reaction to CFLs.
[ ...]
62 information from Dr Maurice Murphy, ME/CFS service, St Bartholomew's
Hospital, London
63 information from Professor Peter White, Professor of Psychological
Medicine, Barts and the London School of medicine and dentistry, St
Bartholomew's Hospital, London.
This was posted this evening on Co-Cure by Stephen Ralph. I'm too brain-dead to discuss it and am certainly not posting it to defend the authors; I'm adding it simply for informational purposes. I'll leave it to others to dissect.
--Marie
----------------------------------
http://www.plosone.org/annotation/listThread.action?inReplyTo=info:doi/1
0.1371%2Fannotation%2F13ea20d1-91e6-49c3-bc4b-8fd1ca18f150&root=info%3Adoi%2
F10.1371%2Fannotation%2F13ea20d1-91e6-49c3-bc4b-8fd1ca18f150
Authors Response
Original Article Failure to Detect the Novel Retrovirus XMRV in Chronic
Fatigue Syndrome
Authors Response
Posted by Anthony_Cleare on 12 Jan 2010 at 19:55 GMT
As the clinicians and scientists who provided the samples that were tested
at Imperial, we wish to respond to some of the comments here and elsewhere
regarding the patients who provided these samples.
In the paper we provided extensive details of the sample selection,
criteria, assessments and investigations that are routine in our service,
together with references/citations to all the material
To re iterate.
1. The criteria that we use are the Fukuda et al 1994 criteria that are far
and away the most widely used across the world and in the research
literature. We do not use the so-called "Canadian criteria", which are
designed for clinical use, not operationalised and do not translate easily
for use in research. Even so, had we attempted to do so, a substantial
proportion would have also met these clinical criteria.
2. The patients resembled those seen in secondary care and tertiary care
services elsewhere - most particularly they are similar to those seen in
clinics in Australia, USA, Scotland, England and Northern Ireland (Wilson et
al, 2001; Hickie et al, 2009).
3. We follow the same psychiatric exclusion criteria as mandated by the
Fukuda criteria. We do this on the basis of semi structured interviews and
assessment that we have also published. In addition, we also exclude
patients with chronic somatisation disorder as defined by DSM-IV, which is
not required by the Fukuda criteria, but most experts and clinicians agree
are a different population. This is only a small percentage of our
referrals.
4. In answer to one question, yes, our patients all report both mental and
physical fatigue, exacerbated by mental or physical effort. Nearly all also
describe post exertional fatigue and malaise.
5. We have a standard laboratory protocol for investigations, which are
performed on all those referred to the clinic, unless they have been done
recently by the referring doctor. These are solely for the purpose of
excluding other diseases that can sometimes mimic CFS, and are part of the
differential diagnosis. This is standard practice in every CFS service of
which we are aware and forms part of every definition of which we are aware,
including the "Canadian criteria". In addition to the standard work up, we
also now routinely test for coeliac disease, because we found a 2%
prevalence of undetected coeliac disease (Skowera et al, 2001). In answer to
another question, we perform a 9.00 am cortisol as a screener for Addison's
disease.
6. In addition we also perform tests as part of research protocols. We
always tell patients that these additional tests and investigations are not
necessary clinically, and are performed with informed consent. Thus patients
in our service have also co operated in studies of PET and fMRI
neuroimaging, autonomic dysfunction, neurochemistry, respiratory function,
vitamin status, anti nuclear antibodies, immune function, neuroendocrine
function and genetics (see references). Hence it is untrue to state that
patients at King's for example do not show alterations in immune function -
in fact they do - see Skowera et al, High levels of type 2
cytokine-producing cells in chronic fatigue syndrome." Clinical and
Experimental Immunology 2004: 135: 294-302. Similarly, many of our patients
also show altered neuroendocrine, neurochemical and other biological
parameters, and we have published many examples of these (see references
below). It is therefore simply untrue that we either seek to find no
biological changes in CFS, or fail to report those that we do find.
7. On the other hand, it is true that those who receive a diagnosis of
cancer would be and are excluded from a diagnosis of CFS and if this is
detected they would be immediately referred to the relevant clinical
services. It is possible that this may be a difference from the cohort
originally reported in Science, if the Wall St Journal is correct
(http://online.wsj.com/art...).
8. We do not perform these additional tests to confirm or refute a diagnosis
of CFS, but to further understanding of the illness. If and when a properly
validated diagnostic test is developed for use within the National Health
Service, all our patients will be offered it free of charge, just as they
are already offered diagnostic assessment, investigation and treatment free
of charge.
9. We did not perform any selection in any shape or form of the samples that
we hold to send to Imperial College, as again has been suggested.
Overall, we wish to emphasis, and to do so emphatically, that our patients
are typical of CFS patients seen in specialist care elsewhere. We
specifically refute the suggestion that our patients are in some way more
"psychiatric", whatever that means, than those with "real CFS", an assertion
that has been repeatedly made in other venues. The rates of co morbid
psychiatric disorder, for which we routinely screen, are again similar to
those seen elsewhere. We draw attention to another study that compared two
services run in the same London teaching hospital, one by an immunologist,
the other a psychiatrist, but showed no fundamental differences between the
two (White et al, 2004). On behalf of the patients that attend our CFS
clinic, we resent the implication that they are in some way different, less
ill, less disabled, let alone less deserving, than CFS patients in any other
service or setting. It is otherwise, and we have provided a wealth of
published data to back this assertion.
Professor Simon Wessely, Professor of Psychological Medicine
Professor David Collier, Professor of Psychiatric Genetics
Dr Anthony Cleare, Reader in Neuroendocrinology
REFERENCES
Allain T, Bearn J, Coskeran P, Jones J, Checkley A, Butler J, McGregor A,
Wessely S, Miell J. Changes in growth hormone, insulin, insulin-like growth
factors (IGFs) and IGF-binding protein-1 in chronic fatigue syndrome. Biol
Psychiatry 1997;41:567-573
Bearn J, Allain T, Coskaran P, Miell J, Butler J, McGregor A, Wessely S.
Neuroendocrine responses to D-fenfluramine and insulin induced hypoglycaemia
in chronic fatigue syndrome. Biological Psychiatry 1995;37:245-252.
Caseras, X., David Mataix-Cols, Vincent Giampietro, Katharine A Rimes,
Michael Brammer, Fernando Zelaya, Trudie Chalder, Emma L Godfrey (2006).
"Probing the working memory system in Chronic Fatigue Syndrome: An fMRI
study using the n-back task." Psychosomatic Medicine 68: 947-955.
Caseras X, M.-C. D., Giampietro V, Rimes KA, Brammer M, Zelaya F, Chalder T,
Godfrey EL (2008). "The neural correlates of fatigue: A fatigue provocation
study in Chronic Fatigue Syndrome." Psychological Medicine 38: 1-11.
Cleare A, Bearn J, Allain T, Wessely S, McGregor A, O'Keane V. Contrasting
neuroendocrine responses in depression and chronic fatigue syndrome. J
Affective Disorder 1995;35:283-289.
Cleare AJ, Sookdeo S, Jones, J, O'Keane V, Miell J. Integrity of the GH/IGF
axis is maintained in chronic fatigue syndrome. Journal of Clinical
Endocrinology and Metabolism, 2000: 85: 1433-1439.
Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V.
Hypothalamo-Pituitary-Adrenal axis function in chronic fatigue syndrome, and
the effects of low-dose hydrocortisone therapy. Journal of Clinical
Endocrinology and Metabolism 2001: 86: 3545-3554.
Cleare AJ Keane, V, Miell JP et al. Levels of DHEA and DHEAS and responses
to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Psychoneuroendocrinology 2004;29:724-32.
Cleare AJ, Messa C, Rabiner E, Grasby P. Brain 5-HT1A receptor binding in
chronic fatigue syndrome measured using positron emission tomography and
[11C]WAY-100635. Biological Psychiatry 2005: 57, 239-246.
Di Giorgio A Hudson, Jerjes W, Cleare AJ. 24-hour pituitary and adrenal
hormone profiles in chronic fatigue syndrome. Psychosomatic Medicine.
2005;67:433-40.
Heap, L., Peters T, Wessely S. Vitamin B status in patients with chronic
fatigue syndrome Journal of the Royal Society of Medicine 1999: 92: 183-185.
Fritz E, Smith J, Kerr J, Cleare A, Wessely S, Mattey D. Association of
chronic fatigue syndrome with human leucocyte antigen class II alleles.
Journal of Clinical Pathology 2005;58:860-863.
Hickie I, Davenport T, Vernon S, Nisenbaum R, Reeves W, Hadzi Pavlovic D,
Lloyd A, Are chronic fatigue and chronic fatigue syndrome valid clinical
entities across countries and health care settings? Australian and NZ
Journal of Psychiatry, 2009; 43:25-35.
Jerjes WK, Cleare AJ, Wessely S, Wood P, Taylor NF. Diurnal patterns of
salivary cortisol and cortisone output in chronic fatigue syndrome J
Affective Disorder 2005: 87: 299-304.
Jerjes WT, NF; Wood, PJ; Cleare, AJ. Enhanced feedback sensitivity to
prednisolone in chronic fatigue syndrome. Psychoneuroendcrinology.
2007;32:192-8.
Jerjes W, Peters T, Taylor N, Wessely S, Cleare A. Diurnal excretion of
urinary cortisol, cortisone and cortisol metabolites in chronic fatigue
syndrome. J Psychosom Res 2006: 60: 145-153
Peakman M, Deale A, Field R, Mahalingam M, Wessely S. Clinical improvement
in chronic fatigue syndrome is not associated with lymphocyte subsets of
function or activation. Clin Immun Immunopath 1997;82:83-91.
Saisch S, Deale A, Gardner W, Wessely S. Hyperventilation and chronic
fatigue syndrome. Quarterly J Medicine 1994: 87:63-67.
Skowera, A., M. Peakman, et al. (2001). "High prevalence of serum markers of
coeliac disease in patients with chronic fatigue syndrome." Journal of
Clinical Pathology 54: 335-336.
Skowera A, Stewart E., Davis E, Cleare A, Hossain G, Unwin C, Hull L, Ismail
K, Wessely S, Peakman M (2002). "Antinuclear antibodies (ANA) in gulf war
related illness and chronic fatigue syndrome (CFS) patients." Clinical
Experimental Immunology 129: 354-358.
Skowera, A., Cleare, A., Blair, D., Bevis, L., Wessely, S., Peakman, M
(2004). "High levels of type 2 cytokine-producing cells in chronic fatigue
syndrome." Clinical and Experimental Immunology 135: 294-302.
Underhill, J., Donaldson P, Mahalingam, M., Wessely A, Peakman M. (2001).
"Lack of association between HLA and chronic fatigue syndrome." European
Journal of Immunogenetics 28: 425-428.
Wilson A, Hickie I, Hadzi-Pavlovic D, Wakefield D. Straus S, Dale J,
McCluskey D, Hinds, G, Brickman A, Goldenberg D, Demitrack M, Wessely S,
Sharpe M, Lloyd A. What is chronic fatigue syndrome? Heterogeneity within an
international, multicenter study. Australian & New Zealand J Psychiatry
2001: 35:520-527
White PD, Pinching AJ, Rakib A, Castle M, Hedge B, Priebe S. A comparison of
patients with chronic fatigue syndrome attending separate fatigue clinics
based in immunology and psychiatry. Journal of the Royal Society of Medicine
2002;95:440-4.
Winkler, A., Blair D, Marsden J, Peters T, Wessely S, Cleare A, (2004).
Autonomic function and serum erythropoetin levels in chronic fatigue
syndrome. Journal of Psychosomatic Research 56: 179-183.
Competing interests declared: Authors of the paper
=========================================
www.ialibrary.berr.gov.uk/.../45. EuP Domestic Lighting_v2 5.doc
Impact Assessment of EuP Implementing Measures of Domestic Lighting
Date: 1st December 2008
[ ... ]
Another clinician Dr Maurice Murphy 62 did not know of any evidence that
demonstrates that CFLs or any other lighting has any effect, detrimental or
otherwise, on CFS/ME. Some patients do indicate light sensitivity, but this
could be part of a general hypersensitivity to various stimuli. Dr Murphy
thought there may be a maladaptive response, for example patients confining
themselves indoors then finding it difficult to adapt to brighter lighting.
Proper evidence would require a controlled study but this would be difficult
practically.
Professor White 63 indicated that he would be surprised if radiation from
low energy lighting had a detrimental effect on patients with CFS/ME, but
would not be surprised if open studies supported such a relationship. This
is because, for some patients, the knowledge that they were being exposed to
radiation reported anecdotally to cause harm would be enough to cause such a
reaction. Dr White was not aware of any studies to test a reaction to CFLs.
[ ...]
62 information from Dr Maurice Murphy, ME/CFS service, St Bartholomew's
Hospital, London
63 information from Professor Peter White, Professor of Psychological
Medicine, Barts and the London School of medicine and dentistry, St
Bartholomew's Hospital, London.